Image by Solera
January 30, 2018 | By Solera

SVR For HCV With No Advanced Liver Disease Greatly Reduces Mortality Risk

A study in the journal Hepatology found that patients diagnosed with hepatitis C who did not have advanced liver disease and attained sustained virologic response after treatment with direct-acting antiviral therapy had a lower mortality risk compared with untreated patients and patients who received DAAs but did not achieve SVR. The study analyzed data from 40,664 Department of Veterans Affairs patients with HCV genotype 1, 2 or 3.

Click Here to view the original article at Specialty Pharmacy Times

A smaller focus to make a much larger impact. Our goal is to deliver on every promise we make

Our Mission

Learn More